ID   TCC-MESO-2
AC   CVCL_E264
SY   Tochigi Cancer Center-MESOthelioma-2
DR   JCRB; JCRB1898
DR   Wikidata; Q54971860
RX   PubMed=19876922;
CC   Population: Japanese.
CC   Doubling time: 26.2 hours (PubMed=19876922).
CC   Transformant: ChEBI; CHEBI_46661; Asbestos.
CC   Derived from site: Metastatic; Bone; UBERON=UBERON_0002481.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
ST   Source(s): JCRB=JCRB1898
ST   Amelogenin: X
ST   CSF1PO: 12,14
ST   D13S317: 9
ST   D16S539: 10,11
ST   D5S818: 10,11
ST   D7S820: 8,12
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 17
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E263 ! TCC-MESO-1
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 14
CH   CVCL_D5HG ! Me2Tu
//
RX   PubMed=19876922; DOI=10.1002/ijc.25002;
RA   Yanagihara, Kazuyoshi
RA   Tsumuraya, Masaru
RA   Takigahira, Misato
RA   Mihara, Keichiro
RA   Kubo, Takanori
RA   Ohuchi, Kazuo
RA   Seyama, Toshio
RT   "An orthotopic implantation mouse model of human malignant pleural
RT   mesothelioma for in vivo photon counting analysis and evaluation of
RT   the effect of S-1 therapy.";
RL   Int. J. Cancer 126:2835-2846(2010).
//